Evidence map›Paper›PMID 40611593›Full record

ArticleImmunotherapy2025

Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study.

Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Hilal Karakaş, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Gökhan Uçar and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Serhat SekmekDepartment of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.ORCID 0000-0003-4650-248X
Hatice BolekDepartment of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.ORCID 0000-0001-8659-7327
Omer Faruk KuzuDepartment of Medical Oncology, University of Health Science, Gülhane Training and Research Hospital, Ankara, Turkey.
Elif Sertesen CamozDepartment of Medical Oncology, University of Health Science, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
Saadet SimDepartment of Medical Oncology, Ege University School of Medicine, İzmir, Turkey.
Hilal KarakaşDepartment of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.
Murad GuliyevDepartment of Medical Oncology, Cerrahpasa School of Medicine, Istanbul, Turkey.
Aysun Fatma AkkusDepartment of Medical Oncology, Trakya University School of Medicine, Edirne, Turkey.
Selver IsıkDepartment of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
Gökhan UçarDepartment of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.
Deniz TuralDepartment of Medical Oncology, University of Health Science, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Cagatay ArslanMedical Point Hospital, Izmir University of Economics, Izmir, Turkey.
Sema Sezin GoksuDepartment of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.ORCID 0000-0002-1222-0444
Ozlem Nuray SeverDepartment of Medical Oncology, Kartal Dr Lutfi Kirdar City Hospital, Istanbul, Turkey.
Nuri KaradurmusDepartment of Medical Oncology, University of Health Science, Gülhane Training and Research Hospital, Ankara, Turkey.ORCID 0000-0003-3291-8062
Cengiz KaracinDepartment of Medical Oncology, University of Health Science, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
Mehmet Ali Nahit SendurDepartment of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.ORCID 0000-0001-7021-6139
Emre YekedüzDepartment of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Yüksel ÜrünDepartment of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.ORCID 0000-0002-9152-9887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the effect of uric acid level on prognosis in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. MATERIALS AND

methodsThis retrospective study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC), which is a multicenter registry encompassing 13 cancer centers across Türkiye. RESULTS AND

conclusionsA total of 189 patients were included in the study. The median age was 61 years in all cohort. Univariable analyses revealed longer TTF (17.87 vs. 6.57 months,

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Renal CellKidney NeoplasmsNivolumabUric AcidAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisRetrospective StudiesTurkeyAntineoplastic Agents, ImmunologicalNivolumabUric AcidbiomarkerImmunotherapykidney cancernivolumabprognosisrenal cell carcinomasurvival

Identifiers

PMID40611593
PMCPMC12269686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.